Health · 1 sources covering this

STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·3h ago
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/9229f29e3d3396918cec42ae0a5dbe593949f7ed"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about pharma seeking to protect China deals, a Roche obesity drug, and more"></iframe>

STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

How 1 sources are covering this

STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

More from Health

STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program

STAT+: Epic’s mortality model, and Omada’s future products

New federal autism committee head has financial ties to leucovorin

Abortion is on the ballot again as post-Roe policies continue to evolve

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Pharmalittle: We&#8217;re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

More from Health

STAT+: Novo may be getting a better deal than expected with Medicare&#8217;s Bridge program

STAT+: Epic&#8217;s mortality model, and Omada&#8217;s future products

New federal autism committee head has financial ties to leucovorin

Abortion is on the ballot again as post-Roe policies continue to evolve

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more

STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program

STAT+: Epic’s mortality model, and Omada’s future products